Chardan initiated coverage of Opus Genetics (IRD) with a Buy rating and $9 price target The firm cites the commercial potential of the company’s gene therapy assets, including OPGx-LCA5 for Leber congenital amaurosis type 5 and OPGx-BEST1 for bestrophinopathies, along with additional upside potential from its partnered phentolamine small molecule programs for the Buy rating.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics’ Promising Prospects: Buy Rating Reinforced by OPGx-LCA5 Efficacy and Strategic Advancements
- Opus Genetics Announces Positive Phase 1/2 Trial Results
- Opus Genetics reports pediatric data from OPGx-LCA5 Phase 1/2 trial
- Opus Genetics reports inducement grant under Nasdaq listing rules
- Promising Clinical Trial Results and Safety Profile Support Buy Rating for Opus Genetics